Fig. 2: OncoPrint view of the genomic landscape of HER2-0 (n = 552) and HER2-low (n = 487) metastatic breast cancer. | Nature Communications

Fig. 2: OncoPrint view of the genomic landscape of HER2-0 (n = 552) and HER2-low (n = 487) metastatic breast cancer.

From: Comprehensive genomic characterization of HER2-low and HER2-0 breast cancer

Fig. 2: OncoPrint view of the genomic landscape of HER2-0 (n = 552) and HER2-low (n = 487) metastatic breast cancer.

a The OncoPrint of ER-negative tumors, divided by HER2 status; b the OncoPrint of ER-positive tumors, divided by HER2 status. Genes are ordered by frequency of variants in the overall study population. Percentages listed show the frequency of alterations in HER2-0 and HER2-low, respectively. All variants represent oncogenic mutations or deep deletions/high amplifications. TMB (mut/mb) is recorded on the top of the plot. HER2 human epidermal growth factor receptor 2, MBC metastatic breast cancer, ER estrogen receptor, TMB tumor mutational burden.

Back to article page